Tuberculosis Bacteria Can Evade Drugs Without “Playing Dead”: Fast-Growing Populations Hide Inside Macrophages

Tuberculosis has long been so difficult to eradicate largely because of a population of nearly dormant bacteria that evade drug attacks through reduced metabolism. However, a study published in *Nature Communications* has identified a very different kind of survivor: rather than slowing down, these bacteria rapidly proliferate inside human immune cells.

The research team developed a high-throughput live-cell imaging method to track *Mycobacterium tuberculosis* inside human macrophages at high temporal and spatial resolution and estimate its proliferation rate at the single-cell level. The results showed that intracellular bacterial populations do not grow at a uniform pace. A small population had a doubling time of less than 10 hours, far faster than the slow growth typically associated with tuberculosis bacteria.

More unexpectedly, these fast-growing subpopulations persisted after treatment with first-line antibiotics. This refers to drug tolerance or evasion and is not equivalent to drug resistance acquired through genetic mutations. The findings indicate that even when bacteria are originally susceptible to a drug, their host-cell environment and physiological state may still affect how effectively they are cleared.

To determine whether the phenomenon observed in cell culture also occurs in living organisms, the team additionally established a mouse model using tuberculosis bacteria with a fluorescent “timer” marker, allowing replication activity to be inferred from fluorescent signals. Single-cell analysis found that host cells carrying large numbers of bacteria also tended to contain bacterial populations with more active replication, supporting the conclusion that fast-growing populations are not an artifact unique to the imaging culture system.

What this discovery revises is not the principle that “slow-growing bacteria can tolerate drugs,” but the boundaries of the tolerance mechanism. If survivors remaining after treatment include both dormant and fast-growing bacteria, targeting only low-metabolic states may miss another pathogen reservoir hidden inside macrophages. Future drug evaluations may also need to consider bacterial growth rate, intracellular location, and host-cell burden together.

However, the current evidence still comes from human cell cultures and mouse models. It has not yet demonstrated that similar fast-growing bacterial populations directly cause relapse or treatment failure in patients, nor has it explained how they form or whether they can be selectively cleared by specific therapies. The paper is also currently an unedited version provided by the journal. Until the findings are validated in clinical samples, this study is better viewed as an important revision to models of tuberculosis bacterial tolerance rather than a basis for changing current treatment regimens.